Distinguished Career Professor
Department of Bioengineering, University of Washington
Director, Molecular Engineering & Sciences Institute
Patrick Stayton currently serves as Distinguished Career Professor in the Department of Bioengineering at the University of Washington. He is the founding Director of the Institute for Molecular Engineering and Sciences. He received his Ph.D. in Biochemistry from the University of Illinois, and was a Postdoctoral Research Associate at the Beckman Institute for Advanced Science and Technology, also at the University of Illinois.
Dr. Stayton's eclectic research group works at the interface of fundamental molecular science and applied molecular bioengineering. His laboratory develops new materials for application to unmet medical needs in the drug delivery, diagnostics, and regenerative medicine fields. He has published over 250 scientific papers. Dr. Stayton has a strong interest in translating the group's research, has been awarded many patents, and is a co-founder of the company Jewel Biotherapeutics based on drugamer and cell therapy work, PhaseRx Inc. (purchased by Arbutus Biopharma) based on his group's biologic drug delivery work, and Nexgenia Inc. based on their cell therapy and diagnostic work.
Dr. Stayton has been elected as a Fellow of the American Institute for Medical and Biological Engineering, and has been the recipient of the Clemson Award from the Society For Biomaterials and the CRS-Cygnus Recognition Award from the Controlled Release Society. He served as Co-Chair of the Gordon Conference on Drug Carriers in Medicine and Biology in 2010. He has also been awarded the 2009 Faculty Research Innovation Award, UW College of Engineering, and the Distinguished Teacher and Mentor Award from the Department of Bioengineering.
1. Das D, Stayton PS, et al. RAFT polymerization of ciprofloxacin prodrug monomers for the controlled intracellular delivery of antibiotics. Polymer Chemistry 2016 7: 826–37.
2. Das D, Stayton PS. et al. Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections. Mol. Pharm. 2017 14: 1988–97.
3. Son HN, et al. Chemotherapeutic copolymers prepared via the RAFT polymerization of prodrug monomers. Polymer Chemistry 2016 7: 4494–505.
4. Procko E, Berguig G, Stayton PS, et al. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell. 2014 Jun 19;157(7): 1644-56.
5. Berguig, GB, Stayton, P.S. et al. ntracellular Delivery System for Antibody–Peptide Drug Conjugates. Molecular Therapy. 2015; 23 (5), 907–917. PubMed PMID: 25669432; PubMed Central PMCID: PMC4427876.